Navigation Links
CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant

iety, in contrast to the leading antidepressants available today that affect only the single neurotransmitter serotonin. This triple action mechanism has the potential for enhanced efficacy while the selective and reversible nature of RIMAs is intended to avoid toxic side effects.

"The excellent safety profile demonstrated in this study is the first confirmation in humans that Tyrima has the potential to deliver on the promise of the RIMA approach, and these positive results represent an important milestone for our company," said Barry Brand, chief executive officer of CeNeRx. "In contrast to other MAO inhibitors, our third generation RIMA series is designed to bind selectively and reversibly, with the goal of significantly reducing the cardiovascular risks and other side effects typically associated with the MAOI class. These safety results, along with the high plasma levels and favorable pharmacokinetics demonstrated in the study, support advancing Tyrima into a multiple dose safety study in late spring."

Tyrima could be the first RIMA antidepressant available in the U.S. market, and it has patent protection through 2026. CeNeRx has worldwide rights to develop and commercialize Tyrima.

The Tyrima Phase l safety trials began in January following a successful review of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration.

About CeNeRx BioPharma

CeNeRx (SEN-er-ex) is a privately held clinical stage company developing and commercializing innovative and improved treatments for diseases of the central nervous system. The company focuses on identifying and developing promising therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. CeNeRx's most advanced compounds, reversible inhibitors of monoamine oxidase, or RIMAs, are in Phase I and late pre-clinical d
'"/>




Page: 1 2 3

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
6. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
7. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
8. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/23/2008)...CISCO, July 23 /- InCode BioPharmaceu... today announced preclinical test,results demonstr...-1 for,the treatment of the rare chronic blood dis...he complete results will be presented at the XXII,...rland, September 28,2008., The only treatment cu...
(Date:7/22/2008)..., Australia, July 22 /- Fol...rday, the Board of Progen,Pharmaceuticals Limited ...ad discontinued the PI-88 phase 3 study in liver c... develop its existing portfolio of compounds and,t...l compounds and,opportunities through Merger & Acq...
(Date:7/22/2008)...wards under Therapeutics Development Initiative br...to 23; next deadline January 20,2009, NEW YORK, ...mission to,speed delivery of transformative treatm...el J. Fox Foundation for Parkinson,s Research has ...try research teams. The awards,were granted under ...
(Date:7/22/2008)...the-Art PET Study Confirms Tyrima Exhibits Excelle...es - - Results Support Initiation of Phase I..., July 22 /- CeNeRx BioPharma,Inc., ...izing innovative,treatments for diseases of the ce...ance its lead candidate Tyrima(TM) into Phase II t...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Quality of Life an Issue in Prostate Cancer Treatment 14764 1Quality of Life an Issue in Prostate Cancer Treatment 14764 2Quality of Life an Issue in Prostate Cancer Treatment 14764 3HHS Secretary Leavitt Praised for Defending Physicians Conscience Rights 14759 1HHS Secretary Leavitt Praised for Defending Physicians Conscience Rights 14759 2Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 1Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 2Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 3Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 4American Idol Spotlights Malaria Crisis During Idol Gives Back April 9 On FOX 14753 1American Idol Spotlights Malaria Crisis During Idol Gives Back April 9 On FOX 14753 2
...-USNewswire/ -- The,following statement may be att...he Advancement of Medical Research (CAMR): , "In t...Bush once,again used the stroke of his veto pen de...d medical research, as well as endanger,the future...,executive order directing NIH to continue pursuin...
...e 2 Diabetes Presented at the,67th Annual Scientif...FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, I...cused on the development,of therapeutics to treat ...on of top line data of its phase 2a study of DIO-9...or for the treatment of,type 2 diabetes. , Results...
Other Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein 2DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein 3
(Date:7/25/2008)...CESS, N.Y., July 25 /PRNewswire-USNewswire/ -- Ant...f Quality Officer and Vice President,of Strategic ...th Fund, a,national foundation committed to improv...ted the foundation,s Program on Health Care Qualit....newscom.com/cgi-bin/prnh/20080725/DC28791LOGO ),...
(Date:7/25/2008)...ON, Calif., July 25 /PRNewswire-FirstCall/ -- Thor...n device-based mechanical,circulatory support ther...,today announced that it will report its operating...hs of fiscal 2008 on Thursday, July 31., The comp...ancial,results and operating activities to all int...
(Date:7/25/2008)...A July 24, 2008 Being overweight or obese is not...ut is also a public health issue that impacts othe...ealth Services Research reveals that the extra Me...ple could place a significant financial burden on ...dollars across the entire current Medicare populat...
(Date:7/25/2008)...July 25 /PRNewswire/ -- BeaconEquity.com announces... news today., Investors can view all of the daily...nEquity.com/m , Today,s Trade Alerts include: DUS...ok Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMed ..., Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis Inc....
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3
...n have Complication as its other name. Among the m...dreaded would be the foot ulcer, as damage can be ... with this dreaded foot ulcer, a boon in disguise ...gh voltage electric current to the skin. //Such an...
...s can also repair damaged ankles claim the researc...ing knee injuries, but it is also a valuable metho...sive surgical technique it is being applied in new... relieve different ankle problems, including ligam...
...ped on a daily basis. One of these latest laser te...ering from a degenerative eye condition. This dege...erneath the retina and leak fluid, causing scarrin...ve come up with a new therapy called the Photodyna...
... reducer Paracetamol, whose active ingredient is A...f the stroke. The fever-reducer acetaminophen lowe...e, according to a new study conducted in The Nethe...ing the first few days, though small enough that t...
Other Medicine News:Health News:Arthroscopy for Ankles 2
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r
ROB-NEL Catheters (100% Latex-Free)
Red Rubber Robinson Catheters (Latex)
Urethral Red Rubber Catheters (Latex)
Medicine Products: